Vlada Hanchar

Vlada Hanchar

Auto-generated profile, based on publicly available information

Vlada Hanchar

Epidemiology Research Unit (EPIUnit), Instituto de Saúde Pública da Universidade do Porto (ISPUP) , Porto

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2026 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
Ko Ko MaungKo Ko Maung
Ko Ko Maung
ETEirini Trichia
Eirini Trichia
HBHenrique Barros
Henrique Barros
VHVlada Hanchar
Vlada Hanchar
JAJesus Alegre-Díaz
Jesus Alegre-Díaz
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
Aims: SCORE2 estimates the 10-year risk of developing non-fatal and fatal cardiovascular disease (CVD), and it was designed for mostly Europeans. However, its transferability to non-European populations has not been extensively studied. The aim of this study was to evaluate the performance of the SCORE2 in ethnically and socioeconomically diverse populations, including those outside of Europe. Methods and results: We leveraged cohort studies from Mexico (N = 95,660, mean age 52.4 years, 32.6% men, mean follow-up 9.7 years), and Portugal (N = 1,216, 52.9 years, 36.9% men, 8.8 years follow-up). SCORE2 has differentially classified frequency of CVD events across levels of risk severity, ranging from 0.7–1.0% CVD events among those with low-moderate risk-profiles, vs. 6.6–9.0% among those with high risk-profiles, respectively. The area under the receiver operating curve (AROC) was 0.762 in Mexico and 0.718 in Portugal. Sensitivities (95% CI) were 85.7 (84.2–87.2) and 95.0 (86.1–99.0), and specificities were 42.8 (42.5–43.1) and 24.3 (21.9–26.9) for Mexico and Portugal, respectively. In all cases, the positive predictive values were below 7%, whereas the negative predictive values were all above 98%. Harrell’s C were 0.717 and 0.692, and Brier’s scores were 0.022 and 0.052 for Mexico and Portugal, respectively. In Mexico, SCORE2 showed good calibration, with a slight overestimation in the higher-risk categories. In Portugal, overestimation in higher-risk categories was more substantial. Conclusion: SCORE2 estimates modest to acceptable performance for predicting the 10-year CVD in Mexicans but performed less favourably in the Portuguese cohort, indicating a need for recalibration.

22 July 2025 in Primary Care Diabetes
Verified
Journal Article
Open access
FKFarnaz Khatami
Farnaz Khatami
PRPien Rawee
Pien Rawee
VHVlada Hanchar
Vlada Hanchar
MBMartin H. de Borst
Martin H. de Borst
SBStephan Bakker
Stephan Bakker
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
We investigated whether adding iron biomarkers into existing type 2 diabetes risk models improves risk prediction. Data from three population-based cohorts were used; CoLaus|PsyCoLaus in Switzerland (5250 participants, 54.9 % females, mean age± standard deviation 51.8 ± 10.5 years, median follow-up of 14.5 years; PREVEND in the Netherlands (4784 participants, 51.8 % females, 52.2 ± 11.5 years, follow-up 7.3 years); and EPIPorto in Portugal (806 participants, 40 % females, 62 ± 13 years, follow-up 7.8 years). The effect of adding iron, ferritin, and transferrin in seven type 2 diabetes risk models was examined. 486 participants (9.3 %) in the CoLaus|PsyCoLaus, 170 (3.6 %) in PREVEND, and 22 (3.4 %) in EPIPorto developed diabetes. There was a substantial association between type 2 diabetes and all risk scores. In the CoLaus|PsyCoLaus and PREVEND, ferritin levels were positively and independently associated with the incidence of diabetes and considerably enhanced its prediction. Transferrin levels were positively and independently associated with the incidence of diabetes across all risk scores in all cohorts and improved its prediction in PREVEND, EpiPorto, and certain risk models in CoLaus|PsyCoLaus. There was found to be no association between iron levels and type 2 diabetes. Adding ferritin or transferrin slightly improved most diabetes risk prediction models.